<DOC>
	<DOCNO>NCT00542997</DOCNO>
	<brief_summary>The objective study ass efficacy , tolerability , safety pharmacokinetics IgPro20 patient primary humoral immunodeficiency ( PID ) .</brief_summary>
	<brief_title>Study Subcutaneous Immune Globulin Patients Requiring IgG Replacement Therapy</brief_title>
	<detailed_description>This study consist 12-week wash-in/wash-out period follow 28-week efficacy period . During 28-week efficacy period , subject visit study site least every 4 week efficacy safety evaluation additionally record detail regard IgPro20 dose certain aspect efficacy safety diary . Pharmacokinetic ( PK ) parameter assess sub-group subject 1 treatment interval steady-state ( Week 28 Â± 1 ) .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Genetic Diseases , X-Linked</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Subjects primary humoral immunodeficiency , namely diagnosis Common Variable Immunodeficiency ( CVID ) define PanAmerican Group Immunodeficiency ( PAGID ) European Society Immunodeficiencies ( ESID ) , Xlinked agammaglobulinemia ( XLA ) define PAGID ESID , Autosomal Recessive Agammaglobulinemia Chest Xray CT scan obtain within 1 year prior enrolment Newly diagnose PID , i.e . subject previously receive immunoglobulin replacement therapy Ongoing serious bacterial infection time screen Malignancies lymphoid cell lymphocytic leukemia , NonHodgkin 's lymphoma immunodeficiency thymoma Allergic severe reaction immunoglobulin blood product associate high antiIgA Additional criterion may apply examination investigator require determine eligibility .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Subcutaneous immune globulin</keyword>
	<keyword>SCIG</keyword>
</DOC>